Milestone Study Reveals PSVT’s Hidden Burden Between Episodes
Event summary
- Milestone Pharmaceuticals presented data at ESC Congress 2026 showing PSVT’s impact on patients’ daily lives between episodes.
- Study found 65% of patients reported fatigue/weakness from chronic PSVT medications as bothersome or extremely bothersome.
- 73% of patients reported daytime activity interruption between PSVT episodes.
- Anxiety persisted between episodes, with 26% of patients reporting extreme anxiety at some point.
The big picture
The study highlights a significant gap in current PSVT management, as existing treatments fail to address the persistent quality-of-life impairments between episodes. This positions Milestone to potentially differentiate its CARDAMYST nasal spray as a more comprehensive solution. The findings also underscore the broader industry trend toward patient-reported outcomes as critical metrics for cardiovascular therapies.
What we're watching
- Treatment Innovation
- How Milestone’s CARDAMYST nasal spray could address the unmet need for at-home PSVT treatment.
- Regulatory Strategy
- Whether this data will support expanded indications or reimbursement arguments for PSVT treatments.
- Market Differentiation
- The pace at which competitors develop treatments targeting PSVT’s between-episode burden.